• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

AbbVie preps for an onslaught of Humira biosimilars in 2023, with Skyrizi and Rinvoq to...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Oct 30, 2022 at 04:42: PM
via Unveiled Friday morning, AbbVie’s Q3 results and earnings call show a company bracing for what could be steep Humira losses with the coming of biosimilar competitors early next year, even as the rest of its immunology franchise outpaces initial expectations.

article source
 




Top Bottom
Back
Quote